DNAnexus and TMA Precision Health Partner to Advance Diagnostics and Treatment Solutions for Rare Diseases
Wednesday, January 24, 2024
DNAnexus, a provider of the Precision Health Data Cloud, and TMA Precision Health, a global health platform for rare diseases, have joined forces to propel basic and translational research for individuals affected by rare diseases. In this collaboration, qualified researchers will gain access to TMA's top-tier whole genome sequencing data and associated longitudinal medical records using the DNAnexus Precision Health Data Cloud and its suite of analysis tools.
This partnership aims to empower scientists to extract crucial translational research insights, ultimately enhancing the selection of diagnostic tests and treatment options for patients grappling with rare disorders. Recent strides in whole genome sequencing have proven instrumental in collecting the extensive data needed to identify unknown etiological variants linked to various rare disorders.
TMA's platform utilizes whole genome sequencing and disease reporting from a global patient pool, linking de-identified data to facilitate large-scale research and broaden cohorts for clinical trials. The DNAnexus Precision Health Data Cloud, renowned for its security, compliance, and scalability, provides scientists with the essential infrastructure to handle, analyze, and collaborate on intricate multimodal data.
Boasting over 40,000 registered users across 48 countries, DNAnexus actively manages more than 80 petabytes of clinical genomic, proteomic, and other multi-omic datasets. The platform strictly adheres to industry standards for data quality, security, privacy, and regulatory compliance.TMA is committed to enhancing accessibility and equity in clinical care for patients grappling with rare diseases.